This page serves as a centralized reference library for the information presented across retatrutidedelivered.com.
Because retatrutide is an investigational medication currently being studied in clinical settings, much of the available information comes from early- to mid-stage research. The goal of this page is not to interpret findings beyond what the evidence supports, but to help readers access original sources and understand where current knowledge comes from.
Mechanism of Action
Safety and Side Effects
Dosage and Administration (Research Context)
Clinical Trials
Each section below groups references by type to make navigation easier.
Retatrutide is being studied as a triple agonist targeting GLP-1, GIP, and glucagon receptors. Foundational research in these pathways provides context for understanding its investigational design.
These studies explore how incretin hormones influence insulin secretion, appetite regulation, and energy balance. They form the biological basis for multi-receptor agonists like retatrutide.
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker DJ. Cell Metabolism.
Multi-hormone Peptides for the Treatment of Obesity and Diabetes
Finan B et al. Nature Reviews Drug Discovery.
Glucagon-like peptide 1 (GLP-1)
Müller TD et al. Molecular Metabolism.
The Physiology of Glucagon-like Peptide 1
Holst JJ. Physiological Reviews.
Research into dual and triple agonists has expanded in recent years, particularly in metabolic disease and weight-related conditions.
These publications examine how combining receptor activity may influence metabolic pathways differently than single- or dual-agonist approaches.
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan B et al. Nature Medicine.
Triple-hormone receptor agonists and metabolic outcomes
Jastreboff AM et al. (Review articles and emerging data)
LY3437943, a novel triple agonist, in preclinical models
Coskun T et al. (Preclinical pharmacology data)
While retatrutide is investigational, it is being studied in the context of broader metabolic research.
These studies provide context for why new therapeutic approaches are being explored and how metabolic regulation is currently understood.
Obesity: Pathophysiology and Clinical Management
Bray GA et al. Lancet.
Pharmacological management of obesity
Wilding JPH et al. New England Journal of Medicine.
Weight management interventions and metabolic outcomes
Lean MEJ et al. The Lancet Diabetes & Endocrinology.
ClinicalTrials.gov is a primary source of publicly available information about ongoing and completed studies involving investigational medications.
A Study of LY3437943 in Participants With Obesity or Overweight
A Study of LY3437943 in Participants With Type 2 Diabetes
Additional phase 2 and phase 3 trials as listed in ClinicalTrials.gov
Clinical trial records provide insight into how retatrutide is being studied, but they do not represent final conclusions. Results may evolve as trials progress or complete.
For deeper context, see the Clinical Trials page.
Retatrutide (also referred to as LY3437943) is being developed by Eli Lilly and Company.
Relevant Materials
Important Context:
These materials may summarize early findings but are not substitutes for peer-reviewed publication. Interpretations should be considered preliminary unless supported by published data.
While retatrutide is investigational, regulatory databases provide context for how medications
Key Resources
Note:
As of current available data, retatrutide has not received full regulatory approval for general clinical use. Always verify status through official regulatory sources.
Hormonal Signaling and Energy Balance
Understanding retatrutide requires familiarity with hormonal regulation.
Key Topics Covered in Literature
Representative Sources
These sources support explanations found on the Mechanism of Action page.
Because retatrutide is still under investigation, safety data is evolving.
Clinical trials typically report
Published trial summaries
(where available)
Conference abstracts
(where available)
ClinicalTrials.gov results sections
(when posted)
For interpretation, see the Safety and Side Effects page.
While not directly about retatrutide, studies on related compounds help contextualize its development.
GLP-1 Receptor Agonists
Dual Agonists
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM et al. NEJM.
Semaglutide in Adults with Overweight or Obesity
Wilding JPH et al. NEJM.
These studies help illustrate how multi-receptor approaches may differ from earlier therapies.
Much of the available data on retatrutide comes from:
Conference presentations
This means:
Conference presentations
Not all completed trials are immediately published in peer-reviewed journals. Some findings may exist only as:
Interim analyses
These sources can be informative but should be interpreted cautiously.
Differences in:
Duration of treatment
can make direct comparisons challenging.
Metabolic research is rapidly evolving. As new data emerges:
Clinical relevance may become clearer
Readers are encouraged to revisit this page periodically for updates.
Common questions about retatrutide, answered objectively
No. Retatrutide is an investigational medication and is not approved for general use. It is currently being studied in clinical trials.
Retatrutide is designed to target three receptors (GLP-1, GIP, and glucagon), whereas many other compounds target one or two. This multi-receptor approach is a key focus of current research.
Some clinical studies have explored changes in body weight as an outcome. While results have generated interest, more research is needed to confirm findings and understand long-term effects.
Safety is still being evaluated. Current research suggests certain side effects may occur, but long-term safety data is not yet fully available.
This is still being studied. Clinical trials typically focus on specific populations, and broader applications—if any—would depend on future research and regulatory review.
There is no confirmed timeline. Approval, if pursued, would depend on the outcomes of ongoing and future clinical trials.
